🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma

Recruitingn/aAges 2 Years - anyAllIstituto Ortopedico Rizzoli
NCT06243588 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

assess whether there is a correlation between some factors (age, sex, tumor volume, tumor site, chemotherapy-induced necrosis, radiation and biomarkers) and overall survival (OS) and relapse-free survival (RFS) in patients with Ewing sarcoma. Identification of reliable prognostic factors could help to identify high-risk patients, which may require a different treatment and follow up.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Male and female patients treated at Rizzoli Orthopaedic Institute between 01/01/1991 and 31/12/2021 * Age ≥ 2 years * Diagnosis of Ewing Sarcoma * Patients with available clinical and imaging data Exclusion Criteria: * At least one inclusion criterion not met
💊

What it tests

  • clinical records review
📍

Where

1 site
IRCCS Itituto Ortopedico Rizzoli
Bologna, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy